1. Home
  2. RELY vs ADPT Comparison

RELY vs ADPT Comparison

Compare RELY & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Remitly Global Inc.

RELY

Remitly Global Inc.

N/A

Current Price

$24.03

Market Cap

5.0B

Sector

Technology

ML Signal

N/A

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

N/A

Current Price

$24.39

Market Cap

4.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RELY
ADPT
Founded
2011
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0B
4.1B
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
RELY
ADPT
Price
$24.03
$24.39
Analyst Decision
Buy
Strong Buy
Analyst Count
7
9
Target Price
$22.86
$17.78
AVG Volume (30 Days)
3.0M
1.7M
Earning Date
05-06-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
263.16
63.89
EPS
1.16
N/A
Revenue
$1,635,147,000.00
$276,976,000.00
Revenue This Year
$21.89
$3.98
Revenue Next Year
$19.17
$22.72
P/E Ratio
$21.41
N/A
Revenue Growth
29.37
54.77
52 Week Low
$12.08
$12.00
52 Week High
$27.48
$26.87

Technical Indicators

Market Signals
Indicator
RELY
ADPT
Relative Strength Index (RSI) 42.80 49.59
Support Level $22.54 $23.92
Resistance Level $25.16 $26.51
Average True Range (ATR) 1.13 1.02
MACD -0.27 -0.30
Stochastic Oscillator 1.15 24.15

Price Performance

Historical Comparison
RELY
ADPT

About RELY Remitly Global Inc.

Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. The company's revenue is generated from transaction fees charged to customers, and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: